Trade Summary

3 days ago, Greenstreet Yvonne, serving as CEO at Alnylam Pharmaceuticals, Inc. (ALNY), sold 6,799 shares at $327.65 per share, for a total transaction value of $2,227,698.00. Following this transaction, Greenstreet Yvonne now holds 99,035 shares of ALNY.

This sale represents a 6.00% decrease in Greenstreet Yvonne's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Alnylam Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.